Entera Bio Board Member, Miranda Toledano To Assume CFO Role
Entera Bio Board Member, Miranda Toledano To Assume CFO Role
Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately.
亞洲網加利福尼亞州聖何塞10月23日電口服大分子療法開發領域的領先企業Entera生物科技有限公司(納斯達克市場代碼：ENTX)今天宣佈，任命Entera公司現有董事會成員米蘭達·託萊達諾為首席商務官、首席財務官和公司戰略主管，即刻生效。
"Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's pipeline and vision. I am excited by the benefit the company will gain with Miranda as part of our leadership team. Her strategic experience is a perfect fit, as we progress through our global partnership discussions and development of our proprietary oral delivery platform."
Entera Bio公司首席執行官斯皮羅斯·賈馬斯評論説：“米蘭達是生物技術行業的傑出領導者，擁有近25年的C級領導、主要投資和資本市場經驗。託萊達諾女士自2018年以來一直擔任我們的董事會成員，她對Entera的流水線和願景有着廣泛的瞭解。我對公司作為我們領導團隊的一員將從Miranda那裏獲得的好處感到興奮。她的戰略經驗是一個完美的契合，因為我們正在通過我們的全球合作伙伴關係討論和我們專有的口頭交付平臺的開發取得進展。
"I am excited to join Entera's management team at this critical juncture in the company's history, as our lead program EB613 prepares to fulfill its potential as the first oral anabolic for the treatment of post-menopausal women at high risk of osteoporosis," commented Miranda Toledano. "EB613 has shown compelling efficacy and safety and there is a clear unmet need for an oral agent to expand the PTH therapeutic class, which is well validated for close to 20 years. Further, Entera will continue to work with strategic partners to broaden our technology to additional high unmet need therapeutic categories, where oral delivery of large molecules is warranted."
米蘭達·託萊達諾評論説：“我很高興能在公司歷史的這個關鍵時刻加入Entera公司的管理團隊，因為我們的主要項目EB613正準備發揮其潛力，成為治療絕經後骨質疏鬆症高風險女性的第一種口服合成藥物。”EB613已經顯示出令人信服的有效性和安全性，而且對於擴大甲狀旁腺素治療類別的口服藥物的需求顯然尚未得到滿足，這一點在近20年的時間裏得到了很好的驗證。此外，Entera將繼續與戰略合作伙伴合作，將我們的技術擴展到更高的未滿足需求的治療類別，在這些類別中，大分子的口服輸送是必要的。“
Ms. Toledano most recently served as Chief Operating Officer, Chief Financial Officer and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (NASDAQ:CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma. Ms. Toledano currently serves as a member of our board of directors as well as a member of the board of directors of Compass Therapeutics (NASDAQ:CMPX), Journey Medical (NASDAQ:DERM) and NEXGEL (NASDAQ:NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
託萊達諾女士最近擔任的職務是TRIGR Treeutics的首席運營官、首席財務官和董事，TRIGR Treeutics是一家專注於腫瘤學、臨牀階段的雙特異性抗體公司，於2021年6月被Compass Treateutics(納斯達克股票代碼：CMPX)收購。在TRIGR，米蘭達負責臨牀開發並領導戰略執行，包括1.17億美元的中國許可證交易和CMPX的收購。此前，託萊達諾曾擔任MLV&Co.(被B.Riley FBR&Co.收購)的醫療保健投資銀行業務主管，在那裏她完成了總計超過40億美元的生物技術股權融資(IPO、ATM和後續融資)。在她職業生涯的早期，託萊達諾曾在Royalty Pharma的投資集團擔任副總裁。託萊達諾女士目前是指南針治療公司(納斯達克股票代碼：CMPX)、啟程醫療公司(納斯達克股票代碼：DERM)和奈克賽爾公司(納斯達克股票代碼：NXGL)的董事會成員。託萊達諾女士擁有塔夫茨大學經濟學學士學位和紐約大學斯特恩商學院金融與創業MBA學位。
About Entera Bio
關於Entera Bio
譯文內容由第三人軟體翻譯。